Alebund Pharmaceuticals
Clinical trials sponsored by Alebund Pharmaceuticals, explained in plain language.
-
New hope for dialysis patients: drug AP301 targets dangerous phosphate levels
Disease control Recruiting nowThis phase 3 trial tests whether AP301, a drug taken with meals, can safely lower high blood phosphate in people on kidney dialysis. About 264 participants will receive either AP301 or a low-dose version for 8 weeks, then all get AP301 for 24 weeks. The goal is to see if AP301 he…
Phase: PHASE3 • Sponsor: Alebund Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill for diabetic kidney disease enters human testing
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called AP303 in 18 people with diabetic kidney disease. The main goal is to check the drug's safety and how the body processes it over two weeks. Participants will be randomly assigned to receive either AP303 or a placebo, and res…
Phase: PHASE1 • Sponsor: Alebund Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC